Mometasone implant for chronic rhinosinusitis

The Propel mometasone-eluting stent (Intersect ENT, Palo Alto, CA) is the first Food and Drug Administration-approved device for delivering steroid medication into the ethmoid cavity following surgery. The implant is composed of a biodegradable polymer in a lattice pattern that expands in a spring-l...

Descripción completa

Detalles Bibliográficos
Autores principales: Wei, Calvin C, Kennedy, David W
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3496965/
https://www.ncbi.nlm.nih.gov/pubmed/23152712
http://dx.doi.org/10.2147/MDER.S33916